Peptides for weight management.
Peptides being studied for weight loss, appetite regulation, and metabolic health.
Inclusion in this category means the peptide is being researched for this purpose — not that it's proven effective. Always consult your healthcare provider.
Semaglutide
Semaglutide is a GLP-1 receptor agonist approved by the FDA in multiple formulations: Ozempic (injectable, T2D), Wegovy (injectable, obesity), and Rybelsus (ora...
Read full profileTirzepatide
Tirzepatide is a once-weekly injectable dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) rece...
Read full profileLiraglutide
Liraglutide is a once-daily injectable glucagon-like peptide-1 (GLP-1) receptor agonist, FDA-approved as Victoza for type 2 diabetes and as Saxenda for chronic ...
Read full profileDulaglutide
Dulaglutide is a once-weekly injectable glucagon-like peptide-1 (GLP-1) receptor agonist, FDA-approved as Trulicity for type 2 diabetes in adults in 2014 and la...
Read full profileOrforglipron
Orforglipron is an important point of clarification for this library: it is NOT a peptide. It is an orally administered, small-molecule (non-peptide) glucagon-l...
Read full profileAOD-9604
AOD-9604 is a modified fragment of human growth hormone (hGH fragment 177-191) that was developed by Metabolic Pharmaceuticals in Australia as an anti-obesity a...
Read full profileCagrilintide
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk for the treatment of obesity. Amylin is a hormone co-secreted with insulin from pancreatic...
Read full profileLipo-C
Lipo-C is a compounded lipotropic injection containing a combination of methionine, inositol, choline (MIC), and typically vitamin B12 (cyanocobalamin or methyl...
Read full profileMazdutide
Mazdutide is a novel dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics (in partnership with Eli Lilly). It is designed to combine the app...
Read full profileSurvodutide
Survodutide is an investigational dual agonist of the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor, developed by Boehringer Ingelheim. It ...
Read full profileRetatrutide
Retatrutide is an investigational once-weekly injectable triple agonist of the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GI...
Read full profileCagriSema
CagriSema is an investigational, fixed-dose, once-weekly subcutaneous combination of two peptides developed by Novo Nordisk: cagrilintide, a long-acting analog ...
Read full profile5-Amino-1MQ
5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular energy metabolism. It was developed as a re...
Read full profileQuestions to ask your doctor about weight management.
- 01 What peptides, if any, have evidence for my specific weight management goals?
- 02 What lab work should I have done before and during any peptide therapy?
- 03 How would this interact with my current medications or health conditions?
- 04 What's a realistic timeline for results based on the current research?
Weight Management research, bias-checked.
Weekly peptide summaries — clinician-reviewed and free of hype.